News zum Sektor Gesundheit aus Norwegen

 

Oslo, 13 October 2024: Reference is made to the stock exchange announcement published by Navamedic ASA (the "Company") on 7 October 2025, regarding the final result of the rights issue in the Company, where a total of 6,046,511 shares were allocated at a subscription price of NOK 21.50 per share, (the "Offer Shares") and the resolution to issue 272,090 new shares, at a subscription price of NOK 21.50 per share, (the "Underwriting Commission Shares") to the underwriters of the Rights issue as settlement of their entitlement to underwriting commission.   The share capital increases...

*Correction: The preliminary count of received subscriptions indicates that 30,159,322 Offer Shares have been subscribed for. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 11 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 10 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 25 September 2025 regarding the launch of a subsequent offering of up to 24,000,000 new shares (the "Offer Shares")...

Oslo, 10 October 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 19 September 2025, regarding notice of an extraordinary general meeting in connection with a private placement to be carried out pursuant to an investment agreement entered into with Songa Capital AS, as announced by the Company on 16 September 2025 (the "Private Placement"). The extraordinary general meeting was held today, on 10 October 2025, at 11:00 hours (CEST). All resolutions proposed by the Company's board of directors...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 10 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 25 September 2025, regarding the launch of a subsequent offering of up to 24,000,000 new shares ("Offer Shares")...

Oslo, Norway, 9 October 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic (“off-the-shelf”) T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of cancer, today announced it has received positive feedback from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) following recent scientific advice. This feedback provides alignment on the preclinical, manufacturing, clinical and regulatory pathway for ZI-MA4-1 and supports Zelluna's planned Clinical Trial Application (CTA) submission later this year....

Um den gesamten Artikel unter 4investors.de zu lesen, klicken Sie bitte auf die Überschrift...

New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression OSLO, Norway, Oct. 8, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up......

Oslo, Norway, October 8, 2025 – Lytix Biopharma AS, a clinical-stage immuno-oncology company, is pleased to announce that its license partner Verrica Pharmaceuticals Inc. will present new data from its Phase II clinical trial of VP-315 (Ruxotemitide, formerly LTX-315) for the treatment of basal cell carcinoma (BCC) at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5–9, 2025 in National Harbor, Maryland, USA.   VP-315 will be featured in both an oral and a poster presentation during the conference. The abstract, titled “Exploratory...

Oslo, 7 October 2025: Reference is made to the stock exchange announcement published by Navamedic ASA (the "Company") earlier today regarding the final result of the rights issue in the Company (the "Rights Issue"). Certain primary insiders, and certain close associates of primary insiders, of the Company have been allocated shares in the Rights Issue: Soleglad Invest AS, a company closely associated with Kathrine Elisabeth Gamborg Andreassen, CEO of the Company, has been allocated 23,260 new shares. Jostein Davidsen, Chairperson of the Board of Directors of the Company, has been...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Oslo, 7 October 2025: Reference is made to the previous stock exchange announcements published by Navamedic ASA (the "Company")...

Oslo, 7 October 2025. With reference to today's webcast, please find enclosed the presentation, also made available at https://observemedical.com/. A recording of the presentation is also available at: Hegnar Media - Observe Medical Trading update 7 october 2025 (https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20251007_1) For further information, please contact: Jørgen Mann, CEO Observe Medical Mobile: +45 408 67 558 E-mail: jorgen.mann@observemedical.com Johan Fagerli, CFO Observe Medical Mobile: +47 958 12 765 E-mail: johan.fagerli@observemedical.com About...

Board-certified oncologist who brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and Clinical Research OrganizationsLONDON--(BUSINESS WIRE)--Epsilogen, the world's leading pan-isotype antibody therapeutic company for the treatment of cancer, today announces the appointment of Cristina Oliva, MD, PhD, as Chief Medical Officer. Dr. Oliva is a Board-certified oncologist and brings global experience across all stages of oncology drug development. Dr. Oliva joins Epsilogen from BerGenBio, where she served as Chief Medical Officer from 2022. Prior to this role, Dr. Oliva was Vice President, Oncology and Head of Oncology Centre of Excellence at IQVIA, where she led a cross-functional team of oncology subject matter experts and established and led the IQVIA Oncology Global Scientific Advisory Board. Dr. Oliva has also held senior positions, leading oncology development programs, at Nordic Nanovector, Takeda Pharmaceuticals, GSK and Eli Lilly. Tim Wilson, CE...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Oslo, 6 October 2025: Reference is made to the previous stock exchange announcements published by Navamedic ASA (the "Company")...

Oslo, 6 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company, OSE ticker "OBSVR") on 25 September 2025 regarding the launch of the subsequent offering of up to 24,000,000 new shares in the Company (the "Subsequent Offering"). The following primary insider has today subscribed for offer shares in the Subsequent Offering through the exercise of subscription rights, as set out below: Line Tønnessen, a Board member of the Company, has exercised 190,858 subscription rights, entitling Line Tønnessen to be allocated 190,858 offer shares in the Subsequent...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Oslo, 6 October 2025: Reference is made to the previous stock exchange announcements published by Navamedic ASA (the "Company")...

Helsinki, Finland, 30 September 2025: The board of Nordhealth AS (the "Company") has today approved the allocation of a maximum of 7,217,260 options linked to the Company's shares under an incentive scheme (the "Options") to members of the Company's executive management and key employees. The Options vest based on a combination of time-based and share price-based performance. The time-based vesting is quarterly, over 4 years (1-year cliff). The performance-based vesting requires a minimum of 11% annual compounding growth in the share price from the start date (i.e. 10% or less annual...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Oslo, 30 September 2025: Reference is made to the previous stock exchange announcements published by Navamedic ASA (the "Company")...

OSLO, NORWAY, September 26, 2025: Microbiome DX company Genetic Analysis AS (“GA”) announces its attendance at the Biomarkers & Precision Medicine congress in London, 30 September - 01 October 2025. The event offers a chance to gain the latest insights from across the biomarker and precision medicine landscape, while providing valuable networking and partnering opportunities. Genetic Analysis' Head of Commercial, Kari Furu, will attend the congress. GA will use the event to highlight GA's microbiome testing platform, GA-map®, demonstrating how it can be used in the development of new...

Oslo, 25 September 2025 – Observe Medical ASA (the "Company" or "Observe Medical") announces further progress in the Italian market. The Company's distributor in Italy has secured a public tender to supply UnoMeter™ products into the largest region in Italy, corresponding to an estimated olume of approximately 240,000 units annually for a period of three years. Following extended cooperation, Observe Medical has also entered into a mutually exclusive distribution agreement with the distributor for the UnoMeter™ product family in Italy. In addition, the Company has received a...